On February 22, 2022 PharmaMar (MSE: PHM) reported that it will host a key opinion leader (KOL) webinar addressed to investors and analysts, entitled "Small Cell Lung Cancer: Today, until Tomorrow, US & EU" on Wednesday, March 9th at 1pm EST/7pm CET (Press release, PharmaMar, FEB 22, 2022, View Source [SID1234608809]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The webinar will feature presentations by Key Opinion Leaders (KOLs) Professor Dr. Benjamin Besse from Institut Gustave Roussy, Villejuif, France and Dr. Jacob Sands from Dana Farber Cancer Institute, Boston. They will discuss the latest research in SCLC and the current landscape in various lines of treatment, including the first-line and relapsed settings. They will also discuss the various unmet medical needs of patients and physicians and present their view on the future treatment paradigm.
This event follows the initiation by PharmaMar of a global randomized phase III study of Zepzelca (lurbinectedin) monotherapy or in combination with irinotecan in relapsed Small Cell Lung Cancer (SCLC) (NCT05153239)1. This trial is expected to serve in a confirmatory capacity in the US following lurbinectedin’s accelerated FDA approval in 2020, as well as a registrational capacity for EMA and other regulatory bodies.
In addition, North America partner Jazz Pharmaceuticals along with its partner Roche Pharmaceuticals initiated a Phase III study assessing the safety and efficacy of lurbinectedin as a first-line maintenance treatment in Small Cell Lung Cancer (SCLC) (NCT05091567)2. If successful, the trial could support an FDA supplemental new drug application, and potentially allow PharmaMar to submit a dossier for registration to the European Medicines Agency. PharmaMar holds full commercial rights for lurbinectedin in Europe and most territories outside the United States and Canada.
The numbers to connect to the teleconference are +34 91 901 16 44 (from Spain), +1 646 664 1960 (from USA or Canada) or +44 20 3936 2999 (other countries). Participant access code: 620352.
The teleconference will be available on PharmaMar’s website by visiting the Events Calendar section of the company’s website at www.pharmamar.com
A recording of the webcast will be made available to accredited investors. To request a link, please feel free to reach out to [email protected].
About Professor Dr. Benjamin Besse
Dr. Benjamin Besse is Professor of Medical Oncology at Paris-Saclay University, Orsay, France and a full-time cancer specialist at Gustave Roussy Cancer Campus, Villejuif, France. Currently, Dr. Besse is Head of the Cancer Medicine Department at Gustave Roussy Cancer Campus and Chair of the EORTC Lung Group. He coordinates the French network for thymic malignancy. His main research interests are application of molecular abnormalities to personalize treatment, circulating biomarkers, early drug development in thoracic tumors and thymic malignancies. He has authored/co-authored more than 250 peer-reviewed papers.
About Dr. Jacob Sands
Dr. Jacob Sands received his MD from the University of Cincinnati in 2005. He completed his residency in internal medicine at the University of California, Davis and fellowship training in hematology/oncology also at the University of California, Davis. He joined the faculty in the Lowe Center for Thoracic Oncology at Dana-Farber in 2017. His research focuses on improved diagnostics and treatments for small cell lung cancer as well as improving lung screening and assisting in the development of lung screening programs throughout the country.